Investing.com - Lyell Immunopharma (NASDAQ: LYEL) reported first quarter EPS of $-0.27, $0.01 worse than the analyst estimate of $-0.26. Revenue for the quarter came in at $65.00K versus the consensus estimate of $0.00.
Lyell Immunopharma's stock price closed at $2.48. It is down -19.48% in the last 3 months and down -52.03% in the last 12 months.
Lyell Immunopharma saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Lyell Immunopharma's stock price’s past reactions to earnings here.
According to InvestingPro, Lyell Immunopharma's Financial Health score is "good performance".
Check out Lyell Immunopharma's recent earnings performance, and Lyell Immunopharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar